Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0D1FC
|
|||
Former ID |
DPR000069
|
|||
Drug Name |
LY-362884
|
|||
Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 2 | [1] | |
Type-2 diabetes [ICD-11: 5A11] | Phase 2 | [1] | ||
Company |
Eli Lilly
|
|||
Structure |
Download2D MOL |
|||
Formula |
C26H29N5O5
|
|||
Canonical SMILES |
CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NCC(COC3=CC=CC4=C3NC(=O)N4)O
|
|||
InChI |
1S/C26H29N5O5/c1-26(2,29-14-18(32)15-35-21-5-3-4-20-23(21)31-25(34)30-20)12-16-6-9-19(10-7-16)36-22-11-8-17(13-28-22)24(27)33/h3-11,13,18,29,32H,12,14-15H2,1-2H3,(H2,27,33)(H2,30,31,34)
|
|||
InChIKey |
RLYDBONATWKYQX-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor beta-3 (ADRB3) | Target Info | Agonist | [1] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Endocytosis | ||||
Salivary secretion | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Beta3 adrenergic receptor signaling pathway | ||||
Reactome | Adrenoceptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.